Biotechs merge to form Aduro BioTech

Berkeley, CA-based Oncologic has merged with Triton BioSystems into a new developer named Aduro BioTech. The combined biotech will focus on developing iron oxide nanoparticles to attack solid tumors. The particles are heated by a magnetic field, killing tumor cells. A spokesman for Aduro told the San Francisco Business Times that Dartmouth researchers will handle much of the early research work. Stephen Isaacs, who founded Cerus, is CEO of Aduro, which has a staff of nine. The report says Aduro has completed a first round of venture capital but declined to say how much money was raised.

- see the merger release
- read the story in the San Francisco Business Times

Suggested Articles

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.

The Big Pharma paid $134 million to enter into the two partnerships but then dropped the projects after Voyager completed research activities.